TW202320811A - Eyewash composition - Google Patents

Abstract

To provide an eyewash composition that contains propylene glycol but yet has excellent antiseptic properties. An eyewash composition contains 0.01 w/v% or more of at least one selected from the group consisting of hyaluronic acid and salts thereof and propylene glycol but does not contain an antiseptic agent selected from quaternary ammonium salt-based antiseptics, paraoxybenzoates, chlorobutanol, and sorbic acids.

Description

Composition for eyewash

The present invention relates to an eyewash composition.

It is thought that the osmotic pressure of the eyewash is preferably adjusted to a value close to tear fluid, and propylene glycol is often formulated as the isotonic agent. However, when propylene glycol is blended, there is a problem of deterioration of corrosion resistance. On the other hand, it is known that antiseptic properties are improved by using preservatives such as benzalkonium chloride (Patent Document 1), but there are concerns about its influence on the cornea or adsorption to contact lenses, and The use of preservatives is undesirable. [Prior art literature] [Patent Document]

[Patent Document 1] Japanese Patent Laid-Open No. 2012-167095

[Problem to be Solved by the Invention] Therefore, an object of the inventors of the present invention is to provide an eyewash composition that is excellent in antiseptic properties while blending propylene glycol.

[Means to solve the problem] The inventors of the present invention conducted diligent research in view of the above-mentioned problems, and as a result, found that by using 0.01 w/v% or more hyaluronic acid in combination with propylene glycol in an eyewash composition, even though no preservative was formulated and propylene glycol was formulated, , Antiseptic properties can also be imparted to the eyewash composition. The present invention has been accomplished after further studies based on this finding, and is disclosed below. Item 1. An eyewash composition containing: (A) 0.01 w/v% or more of at least one selected from the group consisting of hyaluronic acid and its salts, and (B) propylene glycol, and does not contain Ammonium salt-based preservatives, parabens, chlorobutanol and sorbic acid preservatives. Item 2. The eyewash composition according to Item 1, further comprising (C) 0.05 w/v% or more of at least one selected from the group consisting of edetic acid and its salts. Item 3. The eyewash composition according to Item 1 or Item 2, further comprising (D) at least one selected from the group consisting of pyridoxine, chondroitin sulfate, and salts thereof. Item 4. The eyewash composition according to any one of Items 1 to 3, which is used during wearing of contact lenses.

[Effect of the invention] By using 0.01 w/v% or more of at least one selected from the group consisting of hyaluronic acid and its salts in combination with propylene glycol, it is possible to provide a A preservative among esters, chlorobutanol, and sorbic acid, and an eyewash composition with excellent antiseptic properties.

Hereinafter, the embodiments included in the present disclosure will be described in more detail.

The disclosure includes an eyewash composition, which contains at least 0.01 w/v% of at least one selected from the group consisting of hyaluronic acid and its salts, and propylene glycol, and does not contain quaternary ammonium salt-based preservatives, Preservatives in parabens, chlorobutanol and sorbic acid.

At least one selected from the group consisting of hyaluronic acid and its salts (sometimes referred to as component (A)) is a conventionally known substance, and examples of the salt of hyaluronic acid preferably include alkali metal salts such as sodium salts, and the like. These may be used alone or in combination of two or more.

The content of component (A) is not limited as long as it is 0.01 w/v% or more in the eyewash composition of the present disclosure, preferably 0.01 w/v% to 0.08 w/v%, more preferably exemplified It is 0.01 w/v% - 0.02 w/v%, and more preferably, it is 0.015 w/v% - 0.02 w/v%.

Propylene glycol (sometimes referred to as ingredient (B)) is conventionally known. The content of propylene glycol is not limited as long as the effect of the present disclosure can be obtained, but in the eyewash composition, preferably 0.01 w/v% to 2 w/v%, more preferably 0.05 w/v% v% - 1.5 w/v%, more preferably 0.1 w/v% - 1 w/v%. In addition, the content of propylene glycol is not limited as long as the effects of the present disclosure can be obtained, but in the eyewash composition, preferably 1 to 100 parts by mass is exemplified with respect to 1 part by mass of component (A), More preferably, it is 10-55 mass parts, More preferably, it is 20-50 mass parts.

The eyewash composition disclosed herein does not contain preservatives selected from quaternary ammonium preservatives, parabens, chlorobutanol and sorbic acid. The preservative is a known preservative in the fields of eye drops and eye washes. Examples of the quaternary ammonium preservative include aniline ammonium chloride, benzothorium chloride (benzethonium chloride), and the like. Examples of parabens include: parabens such as methyl paraben, propyl paraben, and butyl paraben; salts of parabens (sodium salts) Alkali metal salts, etc.) etc. Examples of sorbic acids include sorbic acid and salts of sorbic acid (alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts, etc.) and the like.

The eyewash composition of the present disclosure may further contain at least one selected from the group consisting of edetic acid and its salts (sometimes referred to as component (C)). Edetic acid is also known as ethylene diamine tetraacetic acid (EDTA), and is conventionally known. Examples of salts of edetate include monosodium edetate, disodium edetate, trisodium edetate, tetrasodium edetate, dipotassium edetate, tripotassium edetate, and tetrapotassium edetate etc. (including hydrates). These may be used alone or in combination of two or more.

When the eyewash composition of the present disclosure contains component (C), the content is not limited as long as the effect of the present disclosure can be obtained, but in the eyewash composition, the component (C) can be exemplified at 0.02w /v% or more, preferably 0.05 w/v% or more, more preferably 0.05 w/v% to 0.1 w/v%, more preferably 0.05 w/v% to 0.08 w/v %. In addition, the content of the component (C) is not limited as long as the effect of the present disclosure can be obtained, but in the eyewash composition, preferably 1 to 8 parts by mass is exemplified with respect to 1 part by mass of the component (A). Parts by mass are more preferably 2 to 6 parts by mass, and more preferably 2.5 to 5 parts by mass.

The eyewash composition of the present disclosure may further contain at least one selected from the group consisting of pyridoxine, chondroitin sulfate, and salts thereof (sometimes referred to as component (D)).

Pyridoxine and salts thereof are known substances and are not limited, but examples of pyridoxine salts include inorganic acid salts such as hydrochloride (pyridoxine hydrochloride) and phosphate.

Chondroitin sulfate is a mucopolysaccharide having a structure in which sulfuric acid, D-glucuronic acid, and N-acetylgalactamine sugar, two repeating sugar chains, are ester-bonded. The salt of chondroitin sulfate is not limited to the present invention, and examples thereof include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; and the like. Although the present invention is not limited, as the salt of chondroitin sulfate, sodium chondroitin sulfate and the like can be exemplified preferably.

Chondroitin sulfate or a salt thereof used in the present disclosure is not limited within the above range, but as its molecular weight, the weight average molecular weight is preferably about 5,000 to 45,000, more preferably about 10,000 to 40,000 , and more preferably about 15,000 to 30,000. The weight average molecular weight can be determined by gel filtration chromatography. Chondroitin sulfate or a salt thereof is commercially available, for example, under the trade name of Japanese Pharmacopoeia Prescription Chondroitin Sulfate Sodium (manufactured by Seikagaku Kogyo Co., Ltd., weight average molecular weight: 20,000).

Pyridoxine or its salt, chondroitin sulfate or its salt may be used alone or in combination of two or more.

When the eyewash composition of the present disclosure contains component (D), the content is not limited as long as the effect of the present disclosure can be obtained, but in the eyewash composition, component (D) is preferably exemplified as 0.001 w/v% - 0.1 w/v%, more preferably 0.01 w/v% - 0.07 w/v%, more preferably 0.04 w/v% - 0.06 w/v%. In addition, the content of the component (D) is not limited as long as the effect of the present disclosure can be obtained, but in the eyewash composition, preferably 1 to 10 parts by mass is exemplified with respect to 1 part by mass of the component (A). Parts by mass are more preferably 2 to 6 parts by mass, and more preferably 2 to 4 parts by mass.

In addition, although the present disclosure is not limited, at least one selected from the group consisting of pyridoxine and its salts is more preferably 0.008 w/v% to 0.01 w/v% in the eyewash composition , and more preferably 0.001 w/v% to 0.01 w/v%, particularly preferably 0.005 w/v% to 0.01 w/v%.

In addition, although the present disclosure is not limited, at least one selected from the group consisting of chondroitin sulfate and its salts is more preferably 0.0055 w/v% to 0.05 w/v% in the eyewash composition , and more preferably 0.01 w/v% to 0.05 w/v%, particularly preferably 0.025 w/v% to 0.05 w/v%.

The eyewash composition of the present disclosure may further contain any other ingredients that are acceptable for eye drops or eyewashes. Although the present disclosure is not limited, examples of the other components include buffers, stabilizers, isotonic agents, solvents (water, etc.), pH regulators, medicinal ingredients, cooling agents, stimulants, thickeners, etc. agent etc. Such other components may be appropriately selected according to purposes and the like as long as they do not interfere with the effects of the present disclosure. One type may be used alone or two or more types may be used in combination, and the compounding amount may be appropriately determined. Furthermore, the components (A) to (D) are also known as medicinal ingredients, stabilizers, thickeners, etc. according to their components, but in this disclosure, the components (A) to ( D) is not contained in any of the other ingredients.

A buffer agent is mentioned as an example of the said other component, Boric acid, borax, etc. are illustrated as a buffer agent. A buffer may be used alone or in combination of two or more. For example, when the composition contains boric acid, the content of boric acid is not limited as long as it does not hinder the effect of the present disclosure. In the composition, it is preferably 0.1 w/v% to 2.5 w/ v%, more preferably 0.5 w/v% to 2 w/v%. For example, when the composition contains borax, the content of borax is not limited as long as it does not hinder the effect of the present disclosure. In the composition, it is preferably 0.005 w/v% to 0.5 w/ v%, more preferably 0.005 w/v% to 0.05 w/v%. The composition may contain buffers other than boric acid and borax, or may not contain buffers other than boric acid and borax. In addition, only any one of boric acid and borax may be prepared in the composition.

When a stabilizer is mentioned as an example of the other components, examples of the stabilizer include: polysorbate (polysorbate 80, polysorbate 60, etc.), polyoxyethylene (polyoxyethylene, POE) hardened castor Sesame oil (POE (80) hardened castor oil, POE (60) hardened castor oil, etc., the numbers in brackets refer to the average added moles of ethylene oxide), POE polyoxypropylene glycol, trometamol, etc. . These may be used alone or in combination of two or more. When the composition contains a stabilizer, its content is not limited as long as it does not hinder the effect of the present disclosure. In the composition, it is preferably 0.01 w/v% to 1 w/v% , more preferably 0.05 w/v% to 0.1 w/v%. In the case where the composition contains a stabilizer, for example, only one selected from polysorbate, POE hardened castor oil, POE polyoxypropylene glycol, and tromethamine may be included, or only two kinds thereof may be included, Moreover, for example, when polysorbate is contained, it can also prepare without compounding POE hardened castor oil, POE polypropylene glycol, and/or tromethamine.

When a medicinal ingredient is mentioned as an example of other ingredients, amino acids, an anti-inflammatory agent, vitamins, an antihistamine, etc. are mentioned as a medicinal ingredient. These may be used alone or in combination of two or more.

Although the present disclosure is not limited, for example, as amino acids, amino acids such as glutamic acid and its salts, salts thereof; amino acid analogs such as taurine, and the like can be illustrated. These may be used alone or in combination of two or more. The eyewash composition disclosed herein can also be prepared without formulating amino acids and/or salts thereof. The so-called amino acid mentioned here refers to an amino acid capable of forming a structural unit of a protein having two functional groups of an amino group and a carboxyl group, for example including L-aspartic acid and the like. In addition, the eyewash composition of the present disclosure can also be prepared without formulating amino acid analogues.

Although the present disclosure is not limited, for example, as an anti-inflammatory agent, zinc sulfate, zinc lactate, ε-aminocaproic acid, allantoin, glycyrrhizic acid (glycyrrhizic acid) and its salts, azulene ) class (chamomile blue, dimethyl isopropyl chamomile blue, dimethylethyl chamomile blue, salts of these, etc.), etc. These may be used alone or in combination of two or more. Although not limiting to the present disclosure, the composition preferably does not contain zinc sulfate and/or zinc lactate. In addition, the composition can also be prepared without blending ε-aminocaproic acid, allantoin, glycyrrhizinic acid and salts thereof.

Although the present disclosure is not limited, examples of vitamins include vitamin A (retinyl palmitate, retinyl acetate, retinol, retinal, retinoic acid, etc.), vitamin B ( Flavin adenine dinucleotide (flavin adenine dinucleotide, cyanocobalamin, etc.), vitamin E (tocopheryl acetate, tocopheryl succinate, tocopheryl nicotinate, tocopheryl linolenate, etc. )wait. These may be used alone or in combination of two or more. Although not limiting to the present disclosure, the composition can also be prepared without at least one vitamin.

Although the present disclosure is not limited, examples of antihistamines include chlorpheniramine and its salts (chlorpheniramine maleate, etc.), diphenhydramine and its salts (diphenhydramine hydrochloride, etc.), etc. These may be used alone or in combination of two or more. The composition of the present disclosure can also be prepared without formulating an antihistamine.

When the composition of the present disclosure contains medicinal ingredients, the content of the medicinal ingredients is not limited as long as the effect of the disclosure is not hindered. In the composition, the content of the medicinal ingredients is preferably 0.05 w/v% - 0.3 w/v%, more preferably 0.1 w/v% - 0.3 w/v%, more preferably 0.2 w/v% - 0.27 w/v%.

When a cooling agent is mentioned as an example of the said other component, Menthol, camphor, borneol, etc. are illustrated as a cooling agent. The cooling agents may be used alone or in combination of two or more. The composition of the present disclosure may contain a cooling agent, or may be prepared without a cooling agent.

When a stimulant is mentioned as an example of the said other component, as a stimulant, aldehydes, such as propionaldehyde, etc. can be illustrated. Although there is no limitation to the present disclosure, the composition disclosed in the present disclosure may contain a stimulant, or may be prepared without a stimulant.

When a thickener is mentioned as an example of the other components, examples of the thickener include alginic acid or its salt, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, salts thereof, glycerin, and the like. These may be used alone or in combination of two or more. The eyewash composition of the present disclosure can also be prepared without formulating these thickeners.

The eyewash composition of the present disclosure can be produced by mixing the above-mentioned component (A) and component (B), if necessary, the above-mentioned component (C), component (D), and the above-mentioned other components. The mixing is not limited as long as these components can be mixed, and what is necessary is to mix them according to a usual procedure.

The pH of the eyewash composition of the present disclosure is not limited as long as it is within the range that can be used as eye drops or eyewash, but at room temperature (25° C.), it can be exemplified from pH 5 to pH 8, and preferably exemplified from pH 5.5 to pH6.5, More preferably, pH5.5-pH6 can be illustrated, More preferably, pH5.5-pH5.8 can be illustrated.

The form of the eyewash composition disclosed in the present disclosure is liquid at room temperature, and as long as the eye can be washed in the same way as the conventionally known method, the method of use is not limited, and it is usually used for eyewashing with an eyecup (eyecup). for eyewashing, or for eyewashing by eye drops.

The eyewash composition disclosed herein can be used with or without contact lenses. Regarding contact lenses, there is no distinction between hard contact lenses and soft contact lenses.

The composition for eyewash of the present disclosure is not limited as long as it can be used as described above, but in the case of using an eyewash cup, it is usually contained in a conventionally known general eyewash container (for example, including a container body, a lid body) can be. The capacity of the container is not limited either, but from the viewpoint of good usability and the like, the capacity is preferably 450 mL to 550 mL.

The eyewash using the eyewash cup can be carried out according to the usual procedures, for example, it can be used in the following way: inject an appropriate amount, such as 4 mL to 6 mL per eye, of the eyewash of the present disclosure from the container into the eyewash cup. Composition Next, the cup was pressed against one side of the eye, the eyewash composition in the cup was brought into contact with the eye, and the eyes were blinked several times.

In addition, when the eyewash composition of the present disclosure is used for eyewashing by eyedrops, it is usually accommodated in an eyedrop container and used. The eye drop container is not limited as long as it can contain the above-mentioned composition for instillation. For example, eye drop containers (for example, container main body, At least two of the middle plug (nozzle) and the cover are integral type). The capacity of the container is not limited, but from the viewpoint of good usability and the like, the capacity can be exemplified as 8 mL to 20 mL.

Eyewashing by eyedrops can be performed by instilling 4 to 6 drops of the eyewashing composition of the present disclosure at a time in accordance with the usual method of use. The dropping amount per drop is also not limited, but it is preferably 35 μL to 40 μL per drop.

According to the eyewash composition of the present disclosure, although no preservative selected from quaternary ammonium salt preservatives, parabens, chlorobutanol and sorbic acid is formulated, by adding 0.01 w/v% or more The use of at least one selected from the group consisting of hyaluronic acid and its salts in combination with propylene glycol can also impart excellent antiseptic properties to the eyewash composition. In addition, by further compounding at least one selected from the group consisting of edetic acid and its salts, or compounding at least one selected from the group consisting of pyridoxine, chondroitin sulfate and their salts, Even if no antiseptic is compounded as shown in the Examples described later, more excellent antiseptic properties can be imparted to the eyewash composition. In addition, when the composition further contains the medicinal ingredient and the like, the effective action due to the medicinal ingredient and the like can be obtained. [Example]

Hereinafter, examples are shown to describe the present disclosure in more detail, but the present disclosure is not limited to these examples.

Test case 1. Preparation of eyewash composition Each component was mixed according to the compounding ratio shown in Table 1 below, and the obtained mixture was passed through a sterile filter (Example 1-Example 5, Reference Example, Comparative Example 1-Comparative Example 3). The pH of each composition was measured immediately after preparation. The pH was measured at room temperature (25° C.) using a desktop pH meter F-52 (manufactured by Horiba Seisakusho Co., Ltd.). In addition, the chondroitin sulfate sodium in the table|surface used the Japanese Pharmacopoeia prescription and medicine specification chondroitin sulfate sodium (weight average molecular weight 20000).

2. Evaluation of preservative power <Candida> Candida (Candida albicans) was suspended in sterilized physiological saline to prepare a bacterial solution (1×10 ⁸ cfu/mL). The bacterial solution was inoculated to 1×10 ⁶ cfu/mL in 10 mL of each composition obtained as described above, and stored at 30° C. in a dark place for 14 days. After storage, 0.1 mL of each composition inoculated with Candida was spread on a commercially available Glucose Peptone with Lecithin & Polysorbate (GPLP) agar medium (GPLP agar medium " Daigo (DAIGO), manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), after culturing at 30°C for 48 hours, the number of colonies was counted visually, and the value obtained by multiplying the count value by 100 was set as 14 since storage. The number of bacteria in each composition after days. The number of bacteria at the time of inoculation was set as 100%, and the ratio (survival rate) of the number of bacteria in each composition after storage for 14 days was calculated. Based on the calculated value, the antiseptic power of the eyewash composition was evaluated according to the following criteria. [Evaluation criteria] ◎: Survival rate decreased to less than 0.1% of the inoculated amount ○: Survival rate decreased to less than 1% of the inoculated amount △: Survival rate decreased to less than 10% of the inoculated amount ×: The criterion for △ was not met

<Staphylococcus aureus> A bacterial liquid (1×10 ⁸ cfu/mL) was prepared by suspending Staphylococcus aureus in sterilized physiological saline. A bacterial solution was inoculated to 1×10 ⁶ cfu/mL in 10 mL of each composition obtained as described above, and stored at 35° C. in a dark place for 14 days. After storage, spread 0.1 mL of each composition inoculated with Staphylococcus aureus on a commercially available soybean lecithin-casein digest-polysorbate (Soya Casein Digest Lecithin Polysorbate, SCDLP) agar medium (SCDLP agar medium "DAIGO", manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), after culturing at 35°C for 48 hours, the number of colonies was counted visually, and the value obtained by multiplying the count value by 100 was set as It is the number of bacteria of each composition after 14 days from storage. The number of bacteria at the time of inoculation was set as 100%, and the ratio (survival rate) of the number of bacteria in each composition after storage for 14 days was calculated. Based on the calculated value, the antiseptic power of the eyewash composition was evaluated in accordance with the same criteria as above.

3. Results The results are shown in Table 1 and Table 2.

[Table 1] (Unit: w/v%) Reference example Comparative example 1 Comparative example 2 Comparative example 3 Example 1 Example 2 Example 3 Example 4 Example 5 Aniline ammonium chloride 0.03 - - - - - - - - Propylene Glycol - 0.5 - 0.5 0.5 0.5 0.5 0.5 0.5 Sodium Hyaluronate - 0.01 0.001 0.01 0.02 0.02 0.01 0.02 Sodium edetate - - - - - - 0.02 0.05 0.05 boric acid 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 Polysorbate 80 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 hydrochloric acid Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount sodium hydroxide Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount purified water The remaining part The remaining part The remaining part The remaining part The remaining part The remaining part The remaining part The remaining part The remaining part total 100 100 100 100 100 100 100 100 100 pH 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 Preservative Power: Candida ◎ x △ △ ○ ○ ○ ◎ ◎

[Table 2] (Unit: w/v%) Example 6 Example 7 Propylene Glycol 0.5 0.5 Sodium Hyaluronate 0.02 0.02 Sodium edetate 0.05 0.05 Sodium Chondroitin Sulfate 0.05 0.05 Pyridoxine hydrochloride - 0.01 boric acid 1.2 1.2 Polysorbate 80 0.05 0.05 hydrochloric acid Appropriate amount Appropriate amount sodium hydroxide Appropriate amount Appropriate amount purified water The remaining part The remaining part total 100 100 pH 5.7 5.7 Preservative Power: Candida ◎ ◎ Antiseptic power: Staphylococcus aureus ○ ◎

The reference example in which aniline ammonium chloride was prepared as a preservative is the positive control (positive control) of this test example, and as shown in Table 1, the evaluation result was ◎, and the preservative power was excellent. On the other hand, in the comparative example 1 which did not mix aniline ammonium chloride but mix|blended propylene glycol, the evaluation result was x, and the desired anticorrosion power was not acquired. In addition, in Comparative Example 2 in which 0.01 w/v% of sodium hyaluronate was formulated without the addition of aniline ammonium chloride or propylene glycol, the evaluation result was △, and the desired antiseptic power was not obtained. In addition, in Comparative Example 3 in which aniline ammonium chloride was not blended but sodium hyaluronate 0.001 w/v% and propylene glycol were blended, the evaluation result was △, and the desired antiseptic power was not obtained.

On the other hand, in Example 1 in which aniline ammonium chloride was not blended and sodium hyaluronate 0.01 w/v% and propylene glycol were blended, the evaluation result was ◯, and the antiseptic power was improved. In Example 2 in which the content of sodium hyaluronate in Example 1 was increased, the evaluation result was also ◯, and the antiseptic power was improved. From this situation, it was surprisingly confirmed that the antiseptic properties of the eyewash composition can be improved by using sodium hyaluronate at 0.01 w/v% or more in combination with propylene glycol having poor antiseptic properties.

In addition, in Example 3 to Example 5 in which edetate sodium was further formulated in Example 1 and Example 2, and Example 6 in which chondroitin sulfate sodium was further formulated in Example 5, and in the implementation In Example 7 in which pyridoxine hydrochloride was further formulated in Example 6, the evaluation result was also ◯ or ⊚, and the antiseptic power was improved. Moreover, when the pH of Example 1-Example 7 was 6.2, the improvement of the corrosion resistance of the same level as Example 1-Example 7 was seen, respectively.

Based on these circumstances, it was confirmed that by using sodium hyaluronate at 0.01 w/v% or more in combination with propylene glycol having poor preservative properties, and further by using sodium edetate, sodium chondroitin sulfate, or pyridoxine hydrochloride in combination, The antiseptic property of the eyewash composition can be improved. In addition, the eyewash compositions of Examples 1 to 7 can improve antiseptic properties without using an aniline ammonium chloride preservative that may be adsorbed to contact lenses, so they can be performed while wearing contact lenses. Wash your eyes.

Prescription The eyewash composition was prepared according to the formulation ratio shown in Table 3, and the preservative power was evaluated by the same method as the test example. As a result, in any eyewash composition of prescription example 1 to prescription example 7, it can be seen that the antiseptic property is the same as that of the practice Example 7 is promoted to the same extent.

[table 3] (Unit: w/v%) Prescription example 1 Prescription example 2 Prescription example 3 Prescription example 4 Prescription example 5 Prescription example 6 Prescription example 7 Propylene Glycol 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Sodium Hyaluronate 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Sodium edetate 0.05 0.05 0.05 0.05 0.05 0.05 0.05 Sodium Chondroitin Sulfate 0.05 0.05 0.05 0.05 0.05 0.05 0.05 Pyridoxine hydrochloride 0.01 0.01 0.01 0.01 0.01 0.01 0.01 ε-aminocaproic acid - 0.2 0.2 0.2 0.2 0.2 0.2 Allantoin 0.03 - - - 0.03 0.03 0.03 Dipotassium Glycyrrhizinate 0.015 - - 0.015 0.015 0.015 0.015 Chlorpheniramine maleate 0.003 0.003 0.003 - 0.003 0.003 0.003 Cyanocobalamin 0.002 0.002 0.002 0.002 0.002 0.002 0.002 tocopheryl acetate - - - 0.005 - - 0.005 l-menthol 0.005 0.005 0.005 0.005 0.005 0.005 0.005 d-borneol 0.002 0.002 0.002 0.002 0.002 0.002 0.002 boric acid 1.6 1.6 1.6 1.6 1.6 1.6 1.6 Borax 0.03 0.03 0.03 0.03 0.03 0.03 0.03 Polysorbate 80 0.01 0.01 0.01 0.01 0.01 0.01 0.01 sodium hydroxide Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount hydrochloric acid Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount purified water The remaining part The remaining part The remaining part The remaining part The remaining part The remaining part The remaining part total 100 100 100 100 100 100 100 pH 5.7 5.7 6.2 6.2 5.7 6.2 5.7

none

none

Claims (4)

An eyewash composition, containing: (A) 0.01 w/v% or more of at least one selected from the group consisting of hyaluronic acid and its salts, and (B) propylene glycol, and does not contain quaternary ammonium salts Preservatives, parabens, chlorobutanol and preservatives in sorbic acid. The eyewash composition according to Claim 1 further contains (C) 0.05 w/v% or more of at least one selected from the group consisting of edetic acid and its salts. The eyewash composition according to Claim 1 or Claim 2 further contains (D) at least one selected from the group consisting of pyridoxine, chondroitin sulfate, and salts thereof. The eyewash composition as described in any one of claim 1 to claim 3 is used in the process of wearing contact lenses.